Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The effect of CASS4 overexpression in facilitating invasion of NSCLC cells was reversed by restoring E-cadherin expression, which indicates that CASS4 may promote invasion by inhibiting E-cadherin expression.
|
27677288 |
2016 |
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The effect of CASS4 overexpression in facilitating invasion of NSCLC cells was reversed by restoring E-cadherin expression, which indicates that CASS4 may promote invasion by inhibiting E-cadherin expression.
|
27677288 |
2016 |
Alzheimer's Disease
|
0.420 |
Biomarker
|
disease |
BEFREE |
Further, Cas scaffolding protein family member 4 could be used as a novel target for the treatment of Alzheimer's disease by inhibiting the protein tyrosine kinase 2 pathway.
|
29789968 |
2018 |
Alzheimer's Disease
|
0.420 |
Biomarker
|
disease |
CTD_human |
Three new AD susceptibility loci, INPP5D, CD2AP, and CASS4, showed specific association with CSF tau biomarkers.
|
30320580 |
2018 |
Presenile dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
|
30320580 |
2018 |
Familial Alzheimer Disease (FAD)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
|
30320580 |
2018 |
Alzheimer Disease, Late Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
|
30320580 |
2018 |
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
|
30320580 |
2018 |
Alzheimer's Disease, Focal Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
|
30320580 |
2018 |
Alzheimer Disease, Early Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
|
30320580 |
2018 |
Dysautonomia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Seventy-five patients with de novo PD underwent a comprehensive autonomic function test and were classified into 2 groups according to the Composite Autonomic Severity Score (CASS; 30 with moderate to severe autonomic dysfunction [CASS 4-10, PD-AUT+] and 45 without significant autonomic dysfunction [CASS 0-3, PD-AUT-]).
|
30796135 |
2019 |
Thromboangiitis Obliterans
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moderate-to-severe active TAO patients (CAS≥5) received intravenous injection of methylprednisolone; mild active patients (3≤CAS≤4) received periocular injection of triamcinolone acetonide.
|
28387769 |
2017 |
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
As the fourth member of the CAS family, CASS4 is also related with positive lymph node metastasis and poor prognosis in lung cancer.
|
27677288 |
2016 |
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
As the fourth member of the CAS family, CASS4 is also related with positive lymph node metastasis and poor prognosis in lung cancer.
|
27677288 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.010 |
Biomarker
|
disease |
BEFREE |
As the fourth member of the CAS family, CASS4 is also related with positive lymph node metastasis and poor prognosis in lung cancer.
|
27677288 |
2016 |
Autonomic nervous system disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Seventy-five patients with de novo PD underwent a comprehensive autonomic function test and were classified into 2 groups according to the Composite Autonomic Severity Score (CASS; 30 with moderate to severe autonomic dysfunction [CASS 4-10, PD-AUT+] and 45 without significant autonomic dysfunction [CASS 0-3, PD-AUT-]).
|
30796135 |
2019 |
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
As the fourth member of the CAS family, CASS4 is also related with positive lymph node metastasis and poor prognosis in lung cancer.
|
27677288 |
2016 |
Progression of non-small cell lung cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the underlying mechanisms and downstream effectors of CASS4 in the development and progression of non-small cell lung cancer (NSCLC) remain unclear.
|
27677288 |
2016 |
Alzheimer's Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.
|
30617256 |
2019 |
Alzheimer's Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
|
24162737 |
2013 |
Alzheimer's Disease
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
|
28199971 |
2017 |
Alzheimer's Disease
|
0.420 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
|
24162737 |
2013 |
Platelet Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Parkinson Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Seventy-five patients with de novo PD underwent a comprehensive autonomic function test and were classified into 2 groups according to the Composite Autonomic Severity Score (CASS; 30 with moderate to severe autonomic dysfunction [CASS 4-10, PD-AUT+] and 45 without significant autonomic dysfunction [CASS 0-3, PD-AUT-]).
|
30796135 |
2019 |